Investigational drug · Phase 2
PF-07104091
Also called: ovarian, SCLC
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Breast Cancer, Solid Tumors, Small Cell Lung Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "PF-07104091"
First trial start
2020
Sep 16, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PF-07104091", any sponsor or status.
Conditions studied
As listed on its trial records.
- Breast Cancer
- Solid Tumors
- Small Cell Lung Cancer
- Ovarian Cancer
Approved drugs for the same conditions: Breast cancer · Small cell lung cancer · Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "PF-07104091" as an intervention, largest first.
- A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid TumorsActive, not recruiting
PfizerPfizer (PFE)
NCT05262400 · 235 participants · Start Mar 14, 2022 · Primary completion Feb 26, 2027
Drug: PF-07220060 + PF-07104091 combination dose escalation; PF-07220060 + PF-07104091 combination dose escalation and 9 more · For: Breast Cancer; Solid Tumors
Sites: Los Angeles, California; Santa Monica, California; Boston, Massachusetts · 44 sites in all
- PF-07104091 as a Single Agent and in Combination TherapyActive, not recruiting
PfizerPfizer (PFE)
NCT04553133 · 157 participants · Start Sep 16, 2020 · Primary completion Dec 31, 2026
Drug: PF-07104091 monotherapy dose escalation; PF-07104091 + palbociclib + fulvestrant and 5 more · For: Small Cell Lung Cancer; Ovarian Cancer; Breast Cancer
Sites: Clive, Iowa; Des Moines, Iowa; Louisville, Kentucky · 22 sites in all
PfizerPfizer (PFE)
NCT05431153 · 30 participants · Start Jun 10, 2022 · Primary completion Oct 17, 2022
Drug: Single dose of PF-07104091 as Tablet Formulation A (Treatment A); Single dose of PF-07104091 as Tablet Formulation B (Treatment B) and 3 more · For: Healthy
Sites: New Haven, Connecticut
PfizerPfizer (PFE)
NCT07127770 · 9 participants · Start Aug 28, 2025 · Primary completion Oct 8, 2025
Drug: PF-07104091 · For: Healthy Adults
Sites: Groningen, Netherlands
Newest research
PubMed records naming it or its code names, newest first.
- Layer-by-layer nanoparticle outer polyelectrolyte impacts protein corona formation.
Dacoba TG, Douglas-Green SA, Murthy B, et al. · Biomaterials 2027
- Jinfeng pills ameliorate levonorgestrel-induced ovarian injury by modulating ApoA1-associated cholesterol homeostasis and PI3K/Akt signaling.
Hu Y, Li G, Ni Q, et al. · J Ethnopharmacol 2027
- Integrated serum pharmacochemistry , network pharmacology, untargeted metabolomics and experimental validation to explore the mechanism of Wenjian Qigong Decoction in the treatment of polycystic ovary syndrome.
Wang X, Liu C, Zhang Z, et al. · J Ethnopharmacol 2027
- Sequential stage-specific administration of Bushen-Tiaojing decoctions II and III ameliorates mitochondrial dysfunction in ovarian granulosa cells of COH mice by regulating GRP75-mediated MAM homeostasis.
Ding X, Wen X, Xiong W, et al. · J Ethnopharmacol 2027
- Zuogui Pill alleviates chemotherapy-induced ovarian aging and oogonial stem cell injury by modulating cGAS-STING-mediated inflammatory signaling.
Zheng Y, Zou Y, An J, et al. · J Ethnopharmacol 2027
- Synaptic remodeling and functional recovery: Huan Le Ning decoction mitigates perimenopausal anxiety and depression symptoms via hippocampal reorganization.
Ma X, Xu Y, Bi Y, et al. · J Ethnopharmacol 2027
Also in development for Breast Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.